Commentary on the guidelines of the European society of cardiology (ESC) regarding the diagnosis and treatment of patients with ST-segment elevation myocardial infarction (STEMI);Kommentare zu den leitlinien der Europäischen gesellschaft für kardiologie (ESC) zur diagnostik und therapie von patienten mit ST-streckenhebungsinfarkt (STEMI)

Kardiologe

Volumn 4, Issue 2, 2010, Pages 84-92

  Silber, S ^a   Borggrefe, M ^a   Hasenfuss G ^a   Falk, V ^a   Kastrati, A ^a   Weis, M ^a   Hamm, C W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Clopidogrel; Myocardial infarction; PCI; Prasugrel; STEMI

Indexed keywords

EID: 77956537110     PISSN: 18649718     EISSN: 18649726     Source Type: Journal    
DOI: 10.1007/s12181-009-0246-6     Document Type: Note

References (30)

1. Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909-2945
2. Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24: 28-66
3. Pinto DS, Kirtane AJ, Nallamothu BK et al (2006) Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 114: 2019-2025
4. Nallamothu BK, Antman EM, Bates ER (2004) Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment? Am J Cardiol 94: 772-774
5. Betriu A, Masotti M (2005) Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 95: 100-101
6. Boersma E (2006) Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27: 779-788
7. Silber S, Albertsson P, Aviles FF et al (2005) Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26: 804-847
8. van de Werf et al (2006) ASSENT-4: Primary versus tenecteplase- facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367: 569-578
9. Bassand JP, Danchin N, Filippatos G et al (2005) Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 26: 2733-2741
10. Widimsky P, Wijns W, Fajadet J et al (2009) Reperfusion therapy for ST-elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (Epub ahead of print)
11. Van't Hof AW, Ernst N, De Boer MJ et al (2004) Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25: 837-846
12. Van't Hof AW, Ten Berg J, Heestermans T et al (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372: 537-546
13. Widimsky P, Tousek P, Rokyta R et al (2009) Routine upfront abciximab vs. standard peri-procedural therapy in patients undergoing primary PCI for cardiogenic shock: the PRAGUE-7 Study. ESC Annual Meeting, Hotline Session, Barcelona
14. Mehilli J, Kastrati A, Schulz S et al (2009) Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119: 1933-1940
15. Stone GW, Webb J, Cox DA et al (2005) Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293: 1063-1072
16. Silva-Orrego P, Colombo P, Bigi R et al (2006) Thrombus aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol 48: 1552-1559
17. Svilaas T, Vlaar PJ, Horst IC van der et al (2008) Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358: 557-567
18. Vlaar PJ, Svilaas T, Horst IC van der et al (2008) Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 371: 1915-1920
19. Spaulding C, Henry P, Teiger E et al (2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355: 1093-1104
20. Di Lorenzo E, De Luca G, Sauro R et al (2009) The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) randomized trial. JACC Cardiovasc Interv 2: 515-523
21. Stone GW, Lansky AJ, Pocock SJ et al (2009) Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360: 1946-1959
22. Silber S, Borggrefe M, Böhm M et al (2007) Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES): Eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28.984 Patienten. Kardiologe 1: 84-111
23. Silber S, Borggrefe M, Böhm M et al (2008) Medikamente freisetzende Koronarstents (DES) und Medikamente freisetzende Ballonkatheter (DEB): Aktualisierung des Positionspapiers der DGK. Clin Res Cardiol 97: 548-563
24. Kirtane AJ, Gupta A, Iyengar S et al (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119: 3198-3206
25. Zeymer U, Gitt AK, Junger C et al (2006) Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 27: 2661-2666
26. Siller-Matula JM, Spiel AO, Lang IM et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157: 148. e1-148.e5
27. O'Donoghue M, Wiviott SD, Antman E et al (2009) The risk of CV events for patients treated with clopidogrel or prasugrel in combination with a proton pump inhibitor. Results from the TRITON-TIMI 38 trial. ESC Annual Meeting, Hotline, Barcelona
28. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015 (Pubitemid 350106708)
29. NICE (2009) Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. http://www.nice.org.uk
30. Steg G, James S, Harrington RA et al (2009) PLATO-STEMI: outcomes in patients with STEMI and planned PCI. AHA, late breaking trials, Orlando